Targeting immunosuppression for cancer therapy.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 23728169.
- Also identified by PMC identifier 3668808.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Failing immunity has been acknowledged for its contribution to cancer development and progression. Recent clinical findings have provided payoffs for significant preclinical evaluation and refinement over the last 20 years, but many questions remain to be answered. In this issue of the JCI, Marabelle et al. describe a novel method for targeting the Tregs that infiltrate tumors, demonstrating that dampening the tumor immunosuppressive environment while activating innate antitumor immunity may be an effective approach to cancer treatment.
Medical subject headings
- Brain Neoplasms
- Lymphoma
- Meningeal Neoplasms
- T-Lymphocytes, Regulatory